Owing to the strong growth guidance over FY21-23E our estimates undergo a revision leading to a revised TP to Rs. 215/share (Rs. 184/share earlier) and multiple of 18x on its FY23E EPS.

Camlin Fine Sciences Ltd. has lost -15.78% in the last 1 Week

Camlin Fine Sciences Ltd.

17 May 2021

190.38

-2.48%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Target

Axis Direct

We maintain our BUY recommendation on CFS and value the stock at 16x FY23E EPS to arrive at a TP of Rs. 184/share, implying an upside of 12% from CMP.

Camlin Fine Sciences Ltd. has gained 89.64% in the last 1 Year

Camlin Fine Sciences Ltd.

19 Feb 2021

190.38

-2.48%

Result Update:Camlin Fine

Buy: Camlin Fine Sciences Ltd.

Axis Direct

We initiate coverage on Camlin Fine Sciences Ltd. (CFS) with a BUY recommendation and a Target Price of Rs. 155, which implies a 46% upside from current levels.

Camlin Fine Sciences.. has an average target of 215.00 from 1 broker.

Camlin Fine Sciences Ltd.

12 Feb 2019

190.38

-2.48%

Camlin Fine Sciences' (CFIN) Q3FY19 consolidated performance was above estimates on reven...

Buy: Camlin Fine Sciences Ltd.

Target

Emkay

Refer to important disclosures at the end of this report Going in right direction; maintain Buy Camlin Fine Sciences' (CFIN) Q3FY19 consolidated performance was above estimates on revenue and PAT front. Revenue up 17% yoy to Rs2.41bn (est. Rs2.29bn); EBITDA up 232% yoy to Rs154mn (est. Rs160mn); with net loss at Rs20mn (est. Rs36mn loss). CFIN's performance is headed in the right direction and well in line with our expectations. The key loss-making subsidiaries in Brazil and China are reaching a breakeven. Further,...

Camlin Fine Sciences Ltd. has lost -39.33% in the last 3 Months

Camlin Fine Sciences Ltd.

17 Feb 2018

190.38

-2.48%

Camlin Fine Sciences' (CFIN) consolidated revenue grew by 54% yoy to Rs2.06bn (Emkay Est....

Buy: Camlin Fine Sciences Ltd.

Emkay

Camlin Fine Sciences' (CFIN) consolidated revenue grew by 54% yoy to Rs2.06bn (Emkay Est. Rs1.97bn) on the back of strong growth traction across key segments like Aroma (698% yoy), Blends (59% yoy), Performance (19% yoy) and Shelf-life (6% yoy). EBITDA stood at Rs46mn, up by 130% yoy but was lower than our estimate of Rs98mn on account of exceptional loss of Rs108mn (Loss: Forex -Rs57mn, China JV -Rs50mn)....

Camlin Fine Sciences Ltd. has gained 89.64% in the last 1 Year

Camlin Fine Sciences Ltd.

06 Sep 2016

190.38

-2.48%

Picks of the week - Camlin Fine Sciences Ltd

Buy: Camlin Fine Sciences Ltd.

HDFC Securities

BUY Camlin Fine Sciences Ltd between Rs. 78- 70 for the target of Rs. 99, 117

Camlin Fine Sciences Ltd. has gained 89.64% in the last 1 Year

Camlin Fine Sciences Ltd.

12 Aug 2016

190.38

-2.48%

Camlin Fine Q1FY17 Update 12Aug2016

Buy: Camlin Fine Sciences Ltd.

Phillip Capital

Key highlights: Consolidated sales (Rs 1.4bn, +14% yoy) were 4% above our estimates. EBITDA margin saw sharp correction to 11.2% (vs. estimated 21.2%) on account of – (1) production disruption in Italy subsidiary for a month period (for implementing efficient technology with target to conserve energy and reduce wastage) and initial marketing spend to launch antioxidant blends in USA. Thus, the EBITDA declined 45% yoy to Rs 157mn. The weak operating performance and higher taxes dragged PAT by 78% yoy to Rs 31mn (estimated Rs 116mn). The weak operating performance was primarily due to quarter specific execution issues at subsidiaries. The standalone financials reported 3% sales growth (to Rs 1.02bn) coupled with 160bps expansion in EBITDA margin (to 17.5%), resulting in 18% yoy growth in profits to Rs 65mn (despite higher tax incidence of 36%). Phillip Capital retain their Buy rating with an unchanged TP of Rs 135 (9x FY18 EV/EBITDA).

Camlin Fine Sciences Ltd. has lost -39.33% in the last 3 Months

Is Camlin Fine Sciences Ltd. worth buying?

240 Votes:

Buy 77.08%

Sell 14.17%

Hold 8.75%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf